

1 Hypothesis-free detection of gene-interaction effects on
2 biomarker concentration in UK Biobank using variance
3 prioritisation

4
5 Matthew S. Lyon (0000-0002-2500-1013),^{1,2*} Louise A. C. Millard,² George Davey Smith,^{1,2}

6 Tom R. Gaunt,^{1,2†} Kate Tilling^{1,2†}

7

8 1. National Institute for Health Research Bristol Biomedical Research Centre, University of
9 Bristol, Oakfield House, Bristol, BS8 2BN, UK

10 2. Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), Bristol Medical
11 School (Population Health Sciences), University of Bristol, Oakfield House, Bristol, BS8
12 2BN, UK

13

14 † These authors contributed equally to this work

15 * To whom correspondence should be addressed. Tel: +44 (0) 117 331 4094; Email:

16 matt.lyon@bristol.ac.uk; Twitter: @matt_s_lyon

17 Abstract

18

19 Blood biomarkers include disease intervention targets that may interact with genetic and
20 environmental factors resulting in subgroups of individuals who respond differently to
21 treatment. Such interactions may be observed in genetic effects on trait variance. Variance
22 prioritisation is an approach to identify genetic loci with interaction effects by estimating
23 their association with trait variance, even where the modifier is unknown or unmeasured.
24 Here, we develop and evaluate a regression-based Brown-Forsythe test and variance effect
25 estimate to detect such interactions. We provide scalable open-source software (varGWAS)
26 for genome-wide association analysis of SNP-variance effects
27 (<https://github.com/MRCIEU/varGWAS>) and apply our software to 30 blood biomarkers in
28 UK Biobank. We find 468 variance quantitative trait loci across 24 biomarkers and follow up
29 findings to detect 82 gene-environment and six gene-gene interactions independent of
30 strong scale or phantom effects. Our results replicate existing findings and identify novel
31 epistatic effects of *TREH* rs12225548 x *FUT2* rs281379 and *TREH* rs12225548 x *ABO*
32 rs635634 on alkaline phosphatase and *ZNF827* rs4835265 x *NEDD4L* rs4503880 on gamma
33 glutamyltransferase. These data could be used to discover possible subgroup effects for a
34 given biomarker during preclinical drug development.

35

36 Introduction

37

38 Blood biomarkers provide valuable information for diagnosis and prognosis of disease¹,
39 insight into biological mechanisms², and a source of causal modifiable risk factors which may
40 be intervened upon to create therapies¹. For example, lipids, glucose, and urate have

41 become successful therapeutic targets for cardiovascular disease³, type 2 diabetes⁴, and
42 gout⁵, respectively, among others. However, as biomarkers are complex traits they are
43 affected by genetic and environmental factors which may interact producing gene-gene
44 (GxG, epistasis) or gene-environment (GxE) effects⁶. Intervening on biomarkers which have
45 an interaction effect on disease outcome will produce subgroup effects with individual
46 variation in response to treatment dependent on the modifier⁷. Identifying these
47 interactions may contribute to stratified medicine which aims to provide optimum
48 treatments and preventative advice for disease based on individual characteristics⁶.

49

50 Detecting interaction effects can be challenging. Statistical power to detect an interaction is
51 lower than for main effects; for randomised control trials the sample size needed to detect
52 an interaction with equal sized subgroups is around four times the size needed to detect the
53 main effect of the same magnitude^{7,8}. Low power is exacerbated by multiple testing
54 correction that is essential to account for evaluating the large numbers of candidate
55 modifiers. To reduce multiple testing, pairwise interaction analyses of SNPs with moderate
56 main effects can be performed. However, this approach could miss subgroups with an effect
57 in only one group or opposing effect directionality (known as qualitative interaction effects⁷)
58 hence weaker overall effects, yet these offer the most potential for stratified medicine. An
59 alternative approach to select SNPs for GxG/GxE testing is variance prioritisation^{9,10} which
60 identifies differences in outcome variance across genotype levels (variance quantitative trait
61 loci, vQTL). Although not conclusive evidence, this observation is consistent with a SNP-
62 interaction effect¹¹ and detection of vQTLs does not require the modifier to be measured¹¹.

63

64 Variance QTLs can arise as a consequence of heterogeneous mean effects that could occur
65 from changing environment, background genetics and temporal regulation¹¹. Among the
66 first reported vQTL effects in humans was rs7202116 (*FTO* locus), associated with a large
67 change in variance (as well as mean) of body mass index (BMI)¹². More recently, systematic
68 testing of vQTL effects on 13 quantitative traits in UK Biobank and subsequent GxE testing
69 identified 16 GxE effects modified by age, sex, physical activity, sedentary behaviour, and
70 smoking¹³. Variance QTLs have also been identified for gene expression¹⁴, DNA
71 methylation¹⁵, Vitamin D¹⁶ and facial morphology¹⁷. To date, gene-interaction studies have
72 mostly focused on testing a small number of candidate interactions, but hypothesis-free
73 testing of vQTL effects on blood biomarkers could lead to the identification of unanticipated
74 intervention targets with subgroup effects.

75

76 Existing studies of vQTLs have employed a range of methods^{13,18-20}. Wang *et al* compared
77 the power and type I error of four widely used variance tests and found the median variant
78 of Levene's test²¹ also known as the Brown-Forsythe test^{13,22} to be most robust. However,
79 this test does not allow for inclusion of covariates or continuous genotype data (i.e.,
80 imputed allelic dose) and does not provide an effect estimate, all of which are limitations
81 when applied in a GWAS. However, the Brown-Forsythe test can be reformulated using
82 least-absolute deviation^{15,23} (LAD) regression using the same structure as the Glejser test²⁴.
83 Regression-based variance tests offer greater flexibility to overcome these limitations.
84 Recent developments in LAD regression have vastly reduced the computational burden for
85 large high-dimensional datasets²⁵.

86

87 In this study we compare the utility of the original Brown-Forsythe test and our LAD
88 regression-based reformulation of the Brown-Forsythe test (LAD-BF) to detect SNP-
89 interaction effects under simulation and develop scalable open-source software
90 (<https://github.com/MRCIEU/varGWAS>) for performing variance GWAS using the latter. We
91 apply our regression-based model to estimate SNP effects on the variance of 30 blood
92 biomarkers in ~337K UK Biobank participants and follow up vQTLs with formal interaction
93 tests to detect GxG and GxE interactions.

94

95 [Material and methods](#)

96

97 [Original Brown-Forsythe test](#)

98

99 The Brown-Forsythe²² test (median variant of Levene's test²¹) refers to the original
100 published non-parametric test and will be used throughout. We applied the Brown-Forsythe
101 test to detect differences in trait variability across the three genotypic groups.

102

103 The test statistic W is F-distributed $F(2, N - 3)$ given by:

104

$$W = \frac{(N - 3)}{2} * \frac{\sum_{i=0}^2 N_i (\bar{X}_i - \bar{X})^2}{\sum_{i=0}^2 \sum_{j=1}^{N_i} (X_{ij} - \bar{X}_i)^2}$$

105

106 Where N is the total number of observations. N_i is the number of observations with the i th
107 genotype group $\{0, 1, 2\}$. X_{ij} is the absolute residual of the outcome for the j th observation

108 in the i th genotype group from the median. \bar{X}_i is the mean of X_{ij} for the i th genotype group
109 and \bar{X} is the mean of X_{ij} across genotype groups.

110

111 All analyses of the original Brown-Forsythe test used the omic-data-based complex trait
112 analysis (OSCA) software package^{13,26} which additionally produces a variance effect estimate
113 derived from the test P-value assuming linearity between the SNP and outcome variance²⁷.

114

115 **LAD-BF test**

116

117 Our reformulated regression-based Brown-Forsythe test uses LAD regression of outcome Y
118 on independent variable X to estimate the residuals adjusting for any covariates:

119

$$Y = \hat{\beta}_0 + \hat{\beta}_1 X + \hat{U}$$

120

121 Where X is the genotype measured by continuous (expected value from genotype
122 imputation) or ordinal (directly genotyped) variable and \hat{U} is the residual of this first-stage
123 model.

124

125 A second-stage ordinary least squares (OLS) model regressed the absolute residuals $|\hat{U}|$ of
126 the first-stage model on the genotype values coded as dummy variables (genotype expected
127 values were rounded to the nearest whole number resulting in some loss of precision)
128 including any covariates given in the first-stage model:

129

$$|U| = \hat{\gamma}_0 + \hat{\gamma}_1 X_1 + \hat{\gamma}_2 X_2 + \hat{E}$$

130

131 The test P-value was estimated from an F-test comparing the second-stage residual sum of
132 squares to an intercept-only model to test the null hypothesis of variability homogeneity
133 across genotypes.

134

135 SNP effects on trait variance were calculated from second-stage regression coefficients
136 which are estimates of mean-absolute deviation. This transformation assumes trait
137 normality.

138 The $var(Y|G == 1)$ was estimated using:

$$2 * \hat{\gamma}_0 + \hat{\gamma}_1 + \hat{\gamma}_1^2 / \left(\frac{2}{p_i}\right)$$

139 The $var(Y|G == 2)$ was estimated using:

$$2 * \hat{\gamma}_0 + \hat{\gamma}_2 + \hat{\gamma}_2^2 / \left(\frac{2}{p_i}\right)$$

140 The standard error of the variance effect was estimated using the delta method²⁸ and
141 heteroscedastic-consistent standard errors for the second-stage model coefficients²⁹.

142

143 LAD regression was implemented using the majorise-minimisation^{25,30} (MM) model with
144 default values for iterations (200) and tolerance (0.001) and first-stage OLS regression
145 coefficients provided as initial values.

146

147 Software

148

149 The LAD-BF test was implemented in varGWAS available in C++ v1.2.3 and R v1.0.0 (refer to
150 the code and data availability section). The MM model used functionality from the cqrReg R-

151 package²⁵ (<https://cran.r-project.org/web/packages/cqrReg/index.html>). OLS and general
152 matrix functionality were provided with Eigen v3.4.0³¹. BGEN file processing used the BGEN
153 library³² v1.1.6.

154

155 The original Brown-Forsythe test used the OSCA software package v0.46^{13,26}. Simulations
156 and follow up UK Biobank analyses were performed using R v3.6.0.

157

158 Simulations

159

160 The bias and statistical power of the two Brown-Forsythe tests were evaluated through a
161 series of simulation studies reported using the ADEMP structure³³ (**Table 1 & Supplemental**
162 **Material and Methods**).

163

164 Participants

165

166 UK Biobank is a large prospective cohort study of approximately 500,000 UK participants
167 aged 37-73 at recruitment³⁴. Recruitment took place between 2006-2010 from across the
168 UK. Measures were collected on lifestyle, socio-demographics, physical parameters, health-
169 related factors, and biological samples for genetic testing and biomarker measurements.
170 Ethical approval for the UK Biobank study was granted by the National Research Ethics
171 Service (NRES) Committee North West (ref 11/NW/0382). All analyses were performed
172 under approved UK Biobank project 15825 (dataset ID 33352).

173

174 Genetic data

175

176 Genetic array data were available on 488,377 participants measured using a combination of
177 UK Biobank Axiom™ array (n=438,398) and UK BiLEVE array (n=49,979). Genotype
178 imputation was performed using a reference set combined with UK10K haplotypes and HRC
179 reference panels with the IMPUTE2³⁵ software as described³⁶. The following SNPs were
180 removed from analysis leaving a total of 6,812,700: multi-allelic loci, minor allele frequency
181 < 5%, Hardy-Weinberg violations ($P < 1 \times 10^{-5}$), genotype missing rate >5%, low imputation
182 score (INFO < 0.3) and *HLA* locus (hg19/GRCh37 chr6:23477797-38448354).

183

184 Quality control

185

186 We applied standard exclusion criteria (**Figure S1**) to remove genotype-phenotype sex
187 mismatches, aneuploidies, and outliers for missingness or heterozygosity as previously
188 described³⁶ leaving n=486,565 participants. To ensure data independence, closely related
189 subjects were removed as described elsewhere³⁶ leaving n=407,176 participants. Finally,
190 ‘non-white British’ participants defined using published methodology³⁶ were removed to
191 avoid confounding by population stratification providing a total sample size of n=377,076.

192

193 Phenotypes

194

195 UK Biobank measures of 30 serum biochemistry markers were available for approximately
196 500k participants. Each measure was chosen based on being an established risk factor for
197 disease, a clinical diagnostic measure or because it characterises a phenotype that is not

198 well assessed by other approaches as described in the UK Biobank documentation³⁷.
199 Quantification and quality control was performed as previously described³⁷. Total physical
200 activity was calculated by summing self-reported duration of walking, moderate and
201 vigorous activity collected using the International Physical Activity Questionnaire as
202 described³⁸. For each analysis participants with missing data were removed. All continuous
203 outcomes were SD normalised.

204

205 Genome-wide association studies (GWAS)

206

207 GWAS of biomarker variability were performed using our LAD regression-based Brown-
208 Forsythe test adjusted for age, sex, and the top ten genetic principal components in first and
209 second regression models. We removed outlier biomarker values with a Z-score > 5SD from
210 the mean to control type I error inflation as previously described¹³. Quality control was
211 undertaken visually using Q-Q plots to check for a departure of P-value distribution from
212 that expected under the null. Independent vQTLs were identified by clumping GWAS loci
213 that passed the experiment-wise genome-wide evidence threshold $P < 1.67 \times 10^{-9}$
214 (Bonferroni correction of standard GWAS threshold: $p = 5 \times 10^{-8} / 30$) using the OpenGWAS
215 API³⁹ with default R^2 threshold of 0.001 and 1000 genomes phase 3 European ancestry⁴⁰.

216

217 Gene interaction test

218

219 Independent vQTLs (see above) were tested for interaction effects on additive and
220 multiplicative scales using heteroscedasticity-consistent standard errors²⁹ adjusted for age,
221 sex, and top ten genetic principal components. To ensure effects were robust to phantom

222 effects⁴¹, we performed sensitivity analyses adjusting for fine-mapped main effects
223 identified using SuSiE⁴² (**Supplemental Material and Methods**). Interactions surpassing
224 genome-wide association significance ($P < 5 \times 10^{-8}$) on additive and multiplicative scales that
225 did not strongly attenuate with adjustment for fine-mapped main effects were prioritised
226 for subgroup analyses. GxG effects were identified through interaction testing with
227 independent ($R^2 < 0.001$) vQTLs excluding pairwise combinations of vQTLs within a 10Mb
228 window as previously described¹³. GxE testing was performed using candidate modifiers:
229 age, sex, body mass index, alcohol intake, smoking status, physical activity, daily sugar
230 intake, and daily fat intake.

231

232 Subgroup analyses

233

234 Subgroup effects of top interaction effects were presented by estimating the SNP effect on
235 the outcome stratified by modifier using heteroscedasticity-consistent standard errors²⁹
236 adjusted for age, sex and top ten genetic principal components. Modifiers were rounded
237 genetic dosage values or prepared by dichotomisation as follows: below or above the
238 median value for continuous variables (group [G] 1, below median; G2, median or greater),
239 ever (G1) vs never (G2) smoker, alcohol intake once a week or more (G1) vs less than once a
240 week on average (G2), males (G1) vs females (G2). Subgroup effects are presented along
241 with the SNP-variance estimates adjusted for age, sex and top ten genetic principal
242 components with and without adjustment for the interaction term (variance effects were
243 not adjusted for sex when sex was the modifier).

244

245 Gene annotation

246

247 Variance QTLs were annotated with the nearest gene using the closest function of
248 bedtools⁴³ (v2.3.0) and Ensembl v104 (GRCh37) protein-coding features which were filtered
249 to retain HUGO⁴⁴ valid identifiers. The following annotations were recoded based on
250 expression QTL evidence^{45,46}: rs4530622 *SLC2A9*, rs11244061 *ABO*, rs71633359 *HSD17B13*,
251 rs28413939 *TREH*, rs281379 *FUT2*, rs635634 *ABO*, rs964184 *APOA5*.

252

253 Results

254

255 Simulated power and type I error to detect interaction effects by change in variance

256

257 The power to detect a difference in trait variability due to an interaction effect was low and
258 equivalent for both methods (**Figure S2**). Suppose a SNP has a main effect on a normally
259 distributed outcome detectable with 80% power, then 10x the sample size needed to detect
260 the main effect was required to detect the interaction with only 50% power assuming the
261 interaction was half the size of the main effect. Positive skew and kurtosis reduced power.
262 Both methods had equally well controlled type I error (**Figure S3**).

263

264 Simulated variance effect estimate and confidence interval coverage

265

266 Under a simulated linear effect of genotype on outcome variance both methods gave the
267 correct effect estimate and 95% confidence interval coverage (**Figure 1**). However, when the
268 difference in variance was a consequence of an interaction effect, the relationship between

269 the genotype and outcome variance was non-linear and dependent on the modifier. Under
270 these conditions, the variance effect estimate produced using OSCA^{26,27} from the Brown-
271 Forsythe test P-value gave the incorrect effect size while LAD-BF produced the correct
272 estimate albeit with slightly elevated coverage.

273

274 Adjusting the LAD-BF test for an interaction effect through simulation

275

276 We simulated an interaction effect and compared the LAD-BF test P-value distributions with
277 and without adjusting for the simulated interaction (**Figure S4**). Including the interaction
278 term in the first-stage regression model completely attenuated the variance test statistic.
279 After identifying an interaction at a variance locus this approach could be applied to
280 determine if additional strong interaction effects exist and could be used in a stepwise
281 regression fashion until all interaction effects are identified.

282

283 Runtime performance

284

285 Increasing the number of CPU threads reduced the total runtime of both methods to
286 process 1000 SNPs (**Figure S5**). For the C++ implementation of LAD-BF in varGWAS, the
287 lowest average runtime was 13.6 second (95% CI 13.5, 13.7) using four threads of an Intel(R)
288 Xeon(R) CPU E5-2680 v4 @ 2.40GHz. Under the same conditions, the original Brown-
289 Forsythe test implemented in OSCA was 1.78x faster (7.61 seconds [95% CI 7.60, 7.63]).

290

291 GWAS of variance effects in UK Biobank

292

293 We identified 468 independent ($R^2 < 0.001$) vQTLs influencing 24 biomarkers (**Figure S6**,
294 **Figure S7 & Table S1**) using an experiment-wise P-value threshold of 1.67×10^{-9} ($5 \times 10^{-8} /$
295 30) and no variance effects for albumin, calcium, oestradiol, phosphate, rheumatoid factor,
296 or total protein. Oestradiol and rheumatoid factor were measured on a subset of $n=76,674$
297 and $n=41,315$ participants respectively and therefore were less well powered to detect
298 effects. Of these vQTLs, 270 (57.7%) had suggestive evidence for a variance effect on the log
299 scale ($P < 5 \times 10^{-5}$) and 453 (96.8%) had a mean effect ($P < 5 \times 10^{-8}$). The low concordance
300 between natural and log scales and high concordance between mean and variance effects
301 suggests the presence of mean-variance relationships which is a likely consequence of
302 extreme non-normality for some of the trait distributions (**Figure S8**).

303

304 Gene-environment interaction effects (GxE)

305

306 We detected 139 additive and 104 multiplicative GxE effects ($P < 5 \times 10^{-8}$; **Figure S9 & Figure**
307 **S10**). Adjusting the additive effects for fine-mapped main effects (**Figure S11**) led to a small
308 increase in *UGT1A8* rs2741047 x sex on direct bilirubin to 0.037 SD (95% CI 0.032, 0.042)
309 from 0.028 SD (95% CI 0.023, 0.033) and minor attenuation of *MAP3K4* rs1247295 x sex on
310 lipoprotein a to -0.011 SD (95% CI -0.015, -0.007) from -0.016 SD (95% CI -0.021, -0.010).
311 These findings could reflect the presence of large main effects in imperfect linkage
312 disequilibrium with the index SNP which is known to inflate/deflate test statistics⁴¹.

313

314 We prioritised 82 GxE effects with evidence on both scales ($P < 5 \times 10^{-8}$) to avoid spurious
315 interactions dependent on scale (**Table S2**). Of these BMI ($n=35$), sex ($n=27$) and age ($n=17$)
316 modified most effects and smoking status ($n=2$) and alcohol intake ($n=1$) fewer. We also

317 tested for interaction by physical activity, and sugar and fat intake but identified little
318 evidence of interactions. The largest effects (**Figure 2**) were: *PNPLA3* rs738409 x BMI on
319 alanine aminotransferase (ALT; 0.08 SD [95% CI 0.08, 0.09]), *SLC2A9* rs938555 x sex on urate
320 (-0.08 SD [95% CI -0.09, -0.08]), *APOE* rs1065853 x sex on low-density lipoprotein (LDL; 0.06
321 SD [95% CI 0.05, 0.07]), *SHBG* rs1799941 x sex on testosterone (0.06 SD [95% CI 0.06, 0.06])
322 and *TM6SF2* rs58542926 x BMI on ALT (0.05 SD [95% CI 0.04, 0.06]). Adjusting the variance
323 effect for the interaction term (**Figure 2**) led to attenuation of *PNPLA3* rs738409 and
324 *TM6SF2* rs58542926 on ALT and *SHBG* rs1799941 on testosterone but strong variance
325 effects on ALT remained at *PNPLA3* rs738409 (LAD-BF $P_{\text{adjust}} = 1.0 \times 10^{-73}$) and *TM6SF2*
326 rs58542926 (LAD-BF $P_{\text{adjust}} = 1.84 \times 10^{-8}$). There was no strong variance attenuation of
327 *APOE* rs1065853 on LDL or *SLC2A9* rs938555 on urate following adjustment for the
328 interaction (**Figure 2**).

329

330 Gene-gene interaction effects (GxG)

331

332 We detected eight GxG effects on the additive scale ($P < 5 \times 10^{-8}$; **Figure S12**), six of which
333 were also associated on the multiplicative scale ($P < 5 \times 10^{-8}$; **Figure S13**). There was no
334 strong attenuation following adjustment for fine-mapped main effects (**Figure S14**)
335 suggesting phantom epistasis^{41,47} was not a major source of bias. *ZNF827* rs4835265 x
336 *NEDD4L* rs4503880 was inversely associated with -0.04 SD (95% CI -0.05, -0.03) gamma
337 glutamyltransferase (GGT), *ABO* rs635634 x *FUT2* rs281379, *ABO* rs635634 x *TREH*
338 rs12225548, and *TREH* rs12225548 x *FUT2* rs281379 were associated with 0.08 SD (95% CI
339 0.07, 0.09), 0.04 SD (95% CI 0.03, 0.05) and 0.02 SD (95% CI 0.02, 0.03) increase in alkaline
340 phosphatase (ALP) respectively, *HSD17B13* rs71633359 x *PNPLA3* rs738409 and *HSD17B13*

341 rs71633359 x *PNPLA3* rs3747207 were associated with -0.04 SD (95% CI -0.05, -0.03) and -
342 0.04 SD (95% CI -0.05, -0.03) decrease in ALT and aspartate aminotransferase (AST)
343 respectively (**Figure 3**). Adjusting the variance effects for the interaction term had no strong
344 impact on the variance estimate (**Figure 3**).

345

346 Discussion

347

348 Here we demonstrate the value of variance GWAS in identifying 468 independent vQTLs
349 with evidence of interaction on 24 serum biochemistry phenotypes in UK Biobank and
350 subsequently identify 82 GxE and six GxG scale independent effects. To facilitate this large-
351 scale analysis on ~337K UK Biobank participants we developed an efficient C++
352 implementation of a LAD regression-based Brown-Forsythe test²² (implemented in
353 varGWAS) with functionality to reliably estimate variance effects and compared the test
354 with the original non-parametric version (implemented in OSCA^{13,26}) through a series of
355 simulations.

356

357 Although the power to detect genetic interaction effects using variance prioritisation was
358 low, when applied to large sample sizes such as UK Biobank strong evidence for association
359 can be identified as demonstrated in this study and by Wang *et al*¹³. We found LAD-BF had
360 several advantages over the original non-parametric test when applied to GWAS. First, LAD-
361 BF directly supports adjustment for covariates (although this could be achieved using the
362 original test if applied to pre-adjusted phenotypes¹³). Second, LAD-BF can test effects of
363 continuous genotypes which enables application to the expected genotype value (“dose”)
364 from imputed SNP array data. Third, our model provides a variance effect estimate which is

365 valid when there is a SNP interaction effect, unlike the implementation of the original
366 Brown-Forsythe test in OSCA which provides an incorrect variance effect estimate derived
367 from the test P-value²⁷. We also demonstrate through simulation that adjusting the variance
368 effect for the interaction term causes attenuation which is useful to determine if other
369 interactions exist and could potentially be applied using stepwise regression until all
370 interaction effects are discovered, subject to sufficient power. However, there are some
371 disadvantages. The runtime was 75% longer than the original test implemented in OSCA,
372 although this is still fast enough to allow large-scale analyses. Second, the effect estimate
373 (but not test statistic) is based on normality assumptions which may be violated in practice.
374

375 The largest GxE effects replicate existing findings: *PNPLA3* rs738409 x BMI on ALT levels^{48,49},
376 *SLC2A9* rs938555 x sex on urate⁵⁰, *APOE* rs1065853 x sex on LDL⁵¹, *SHBG* rs1799941 x sex on
377 testosterone⁵², and *TM6SF2* rs58542926 x BMI on ALT⁴⁸. Adjusting the variance effect for
378 the interaction led to attenuation of *PNPLA3* rs738409 and *TM6SF2* rs58542926 on ALT and
379 *SHBG* rs1799941 on testosterone, however strong evidence of variance effects remained for
380 ALT at *PNPLA3* rs738409 and *TM6SF2* rs58542926 suggesting other interaction effects may
381 exist at these loci. The variance effect of *SHBG* rs1799941 on testosterone was weak after
382 adjusting for rs1799941 x sex suggesting no strong evidence of further interaction effects on
383 testosterone at this locus, but the test may be underpowered to detect additional effects.
384

385 We replicated previous GxG effects of *ABO* rs635634 x *FUT2* rs281379 on ALP^{53,54} and
386 *HSD17B13* rs71633359 x *PNPLA3* rs738409/rs3747207 on ALT and AST^{55,56} and find no
387 strong evidence of 'phantom epistasis'^{41,47} as a potential explanation. Additionally, we
388 identified novel effects of *TREH* rs12225548 x *FUT2* rs281379 and *ABO* rs635634 x *TREH*

389 rs12225548 on ALP and *ZNF827* rs4835265 x *NEDD4L* rs4503880 on GGT. ABO blood group
390 antigens and secretion status are thought to influence ALP clearance^{57,58}. *TREH* rs12225548
391 has a strong main effect on ALP^{39,59,60} and interactions of these loci may be explained by
392 interplay of ALP production and clearance mechanisms. *ZNF827* and *NEDD4L* loci have
393 previously been reported to influence GGT levels in independent populations but the
394 mechanism is unclear^{61,62}.

395

396 None of the GxG loci variance effects strongly attenuated after adjusting for the interaction
397 term. This could be a consequence of low power since the interaction effect likely explains a
398 very small amount of the trait variance but could also indicate the presence of other
399 interaction effects involving the same SNP not included in the variance model. Indeed, we
400 found strong GxE evidence at some of these loci: *ABO* rs635634 x sex on ALP, *HSD17B13*
401 rs71633359 x BMI and *PNPLA3* rs738409/rs3747207 x BMI on ALT and AST.

402

403 Evidence of gene-interaction effects could suggest the protein product also has an
404 interaction effect. In which case interventions developed to target the protein will show
405 differential effects on the indication and could have low or no efficacy in some subgroups⁶³.

406 Such evidence could be important to support developments in stratified medicine.

407 Therefore, vQTL evidence may have a role in preclinical drug development to deprioritise
408 targets given the possibility of target-outcome heterogeneous effects. Further research is
409 needed to appraise the utility of vQTLs in the drug development pipeline as has been done
410 for protein QTLs⁶⁴.

411

412 However, there are other explanations for vQTLs that are not in terms of biology. First, loci
413 that are weakly correlated with a SNP having a strong main effect can introduce a phantom
414 vQTL^{65,66}. In this situation variance is introduced through variability in LD between the
415 artefactual vQTL and QTL. Second, vQTLs could signify fluctuation of a trait measurement
416 within an individual over time¹⁰ and may originate from normal biological processes such as
417 circadian rhythm. Third, we assume homogeneity of variance within each genotype group
418 which could be violated by the mean-variance relationship and observed low concordance
419 of vQTL effects on the log and natural scales are evidence for this. Additionally, our
420 interactions could be explained by non-linear relationships between the exposure and
421 outcome or scale artefacts⁶⁷. We sought to reduce the latter by replicating effects on
422 additive and multiplicative scales.

423

424 Through this work we performed hypothesis-free analyses of genetic interaction effects on
425 30 blood biomarkers in UK Biobank using variance prioritisation and found evidence for 88
426 effects. Many of our top findings replicate previously reported associations, but we also
427 report first evidence of *TREH* rs12225548 x *FUT2* rs281379 and *TREH* rs12225548 x *ABO*
428 rs635634 on ALP and *ZNF827* rs4835265 x *NEDD4L* rs4503880 on GGT. Additionally, we
429 show variance attenuation of *PNPLA3* rs738409 and *TM6SF2* rs58542926 on ALT and *SHBG*
430 rs1799941 on testosterone after adjusting for the interaction indicating these effects were
431 contributing to the variance association, but the ALT effects were still strong suggesting
432 additional interactions may exist at these loci. These data could be used to discover possible
433 subgroup effects for a given biomarker during preclinical drug development. To facilitate our
434 analysis, we developed C++ variance GWAS software that implements a LAD-regression
435 based Brown-Forsythe test, provide a convenient R-package based on this software and

436 introduce methodology to estimate the variance effects which can be applied to other
437 studies.

438

439 [Supplemental information description](#)

440

441 Supplemental Material and Methods

442 Figure S1. UK Biobank participant inclusion criteria

443 Figure S2. Power to detect SNP-interaction effects using variance testing under simulation

444 Figure S3. Type I error of Brown-Forsythe tests

445 Figure S4. Effect of adjustment for the interaction effect on variance test P-value

446 distribution

447 Figure S5. Runtime performance of varGWAS and OSCA

448 Figure S6. Manhattan plots of biomarker variance GWAS using regression-based Brown-

449 Forsythe test

450 Figure S7. Q-Q plots of biomarker variance GWAS using regression-based Brown-Forsythe

451 test

452 Figure S8. Biomarker distribution

453 Figure S9. Top gene-by-environment interaction effects ($P < 5 \times 10^{-8}$) on biomarker

454 concentration using additive scale

455 Figure S10. Top gene-by-environment interaction effects ($P < 5 \times 10^{-8}$) on biomarker

456 concentration using multiplicative scale

457 Figure S11. Top gene-by-environment interaction effects ($P < 5 \times 10^{-8}$) on biomarker

458 concentration using additive scale adjusted for fine-mapped main effect

459 Figure S12. Top gene-by-gene interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration
460 using additive scale

461 Figure S13. Top gene-by-gene interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration
462 using multiplicative scale

463 Figure S14. Top gene-by-gene interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration
464 using additive scale adjusted for fine-mapped main effects

465 Table S1. GWAS summary statistics for top vQTLs identified through this study

466 Table S2. Top GxG/GxE effect summary statistics

467 Table S3. Fine-mapped loci covariates

468

469 [Declaration of Interests](#)

470

471 T.R.G receives funding from Biogen for unrelated research. K.T has been paid for
472 consultancy for CHDI.

473

474 [Acknowledgements](#)

475

476 This study was funded by the NIHR Biomedical Research Centre at University Hospitals
477 Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed
478 are those of the author(s) and not necessarily those of the NIHR or the Department of
479 Health and Social Care. This work was also funded by the UK Medical Research Council as
480 part of the MRC Integrative Epidemiology Unit (MC_UU_00011/1, MC_UU_00011/3 and
481 MC_UU_00011/4). L.A.C.M is funded by a University of Bristol Vice-Chancellor's fellowship.

482

483 [Code and data availability](#)

484

485 Software to perform variance GWAS using the LAD Brown-Forsythe model is available from

486 <https://github.com/MRCIEU/varGWAS> and R-package for *ad hoc* analyses is available from

487 <https://github.com/MRCIEU/varGWASR>. Code for performing simulation studies is available

488 from <https://github.com/MRCIEU/varGWAS/sim>. Code for running the UK Biobank analysis

489 is available from <https://github.com/MRCIEU/varGWAS-ukbb-biomarkers>. Full variance

490 GWAS summary statistics are available from the OpenGWAS project^{39,68}. All code

491 repositories are available under the GPL v3 license.

492 References

493

494 1. Holmes, M. V., Richardson, T.G., Ference, B.A., Davies, N.M., and Davey Smith, G. (2021).

495 Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular
496 drug development. *Nat. Rev. Cardiol.* *18*, 435–453.

497 2. Chen, V.L., Du, X., Chen, Y., Kuppa, A., Handelman, S.K., Vohnoutka, R.B., Peyser, P.A.,

498 Palmer, N.D., Bielak, L.F., Halligan, B., et al. (2021). Genome-wide association study of serum
499 liver enzymes implicates diverse metabolic and liver pathology. *Nat. Commun.* 2021 121 *12*,

500 1–13.

501 3. Pekkanen, J., Linn, S., Heiss, G., Suchindran, C.M., Leon, A., Rifkind, B.M., and Tyroler, H.A.

502 (2010). Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level

503 among Men with and without Preexisting Cardiovascular Disease. *NEJM* *322*, 1700–1707.

504 4. Diabetes Prevention Program Research Group (2002). Reduction of the incidence of type

505 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* *34*, 162–163.

506 5. Seth, R., Kydd, A.S., Buchbinder, R., Bombardier, C., and Edwards, C.J. (2014). Allopurinol

507 for chronic gout. *Cochrane Database Syst. Rev.* *2014*.

508 6. Hunter, D.J. (2005). Gene–environment interactions in human diseases. *Nat. Rev. Genet.*

509 2005 *6*, 287–298.

510 7. Brookes, S.T., Whitely, E., Egger, M., Davey Smith, G., Mulheran, P.A., and Peters, T.J.

511 (2004). Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power

512 and sample size for the interaction test. *J. Clin. Epidemiol.* *57*, 229–236.

513 8. Smith, P.G., and Day, N.E. (1984). The Design of Case-Control Studies: The Influence of

514 Confounding and Interaction Effects. *Int. J. Epidemiol.* *13*, 356–365.

515 9. Deng, W.Q., and Paré, G. (2011). A fast algorithm to optimize SNP prioritization for gene-

- 516 gene and gene-environment interactions. *Genet. Epidemiol.* 35, 729–738.
- 517 10. Paré, G., Cook, N.R., Ridker, P.M., and Chasman, D.I. (2010). On the Use of Variance per
518 Genotype as a Tool to Identify Quantitative Trait Interaction Effects: A Report from the
519 Women’s Genome Health Study. *PLoS Genet.* 6, e1000981.
- 520 11. Rönnegård, L., and Valdar, W. (2012). Recent developments in statistical methods for
521 detecting genetic loci affecting phenotypic variability. *BMC Genet.* 2012 131 13, 1–7.
- 522 12. Yang, J., Loos, R.J.F., Powell, J.E., Medland, S.E., Speliotes, E.K., Chasman, D.I., Rose, L.M.,
523 Thorleifsson, G., Steinthorsdottir, V., Mägi, R., et al. (2012). FTO genotype is associated with
524 phenotypic variability of body mass index. *Nature* 490, 267–272.
- 525 13. Wang, H., Zhang, F., Zeng, J., Wu, Y., Kemper, K.E., Xue, A., Zhang, M., Powell, J.E.,
526 Goddard, M.E., Wray, N.R., et al. (2019). Genotype-by-environment interactions inferred
527 from genetic effects on phenotypic variability in the UK Biobank. *Sci. Adv.* 5, eaaw3538.
- 528 14. Brown, A.A., Buil, A., Viñuela, A., Lappalainen, T., Zheng, H.F., Richards, J.B., Small, K.S.,
529 Spector, T.D., Dermitzakis, E.T., and Durbin, R. (2014). Genetic interactions affecting human
530 gene expression identified by variance association mapping. *Elife* 2014, e01381.
- 531 15. Staley, J.R., Windmeijer, F., Suderman, M., Lyon, M.S., Davey Smith, G., and Tilling, K.
532 (2021). A robust mean and variance test with application to high-dimensional phenotypes.
533 *Eur. J. Epidemiol.* 1, 1–11.
- 534 16. Revez, J.A., Lin, T., Qiao, Z., Xue, A., Holtz, Y., Zhu, Z., Zeng, J., Wang, H., Sidorenko, J.,
535 Kemper, K.E., et al. (2020). Genome-wide association study identifies 143 loci associated
536 with 25 hydroxyvitamin D concentration. *Nat. Commun.* 2020 111 11, 1–12.
- 537 17. Liu, D., Ban, H.-J., El Sergani, A.M., Lee, M.K., Hecht, J.T., Wehby, G.L., Moreno, L.M.,
538 Feingold, E., Marazita, M.L., Cha, S., et al. (2021). PRICKLE1 × FOCAD Interaction Revealed by
539 Genome-Wide vQTL Analysis of Human Facial Traits. *Front. Genet.* 0, 1112.

- 540 18. Young, A.I., Wauthier, F.L., and Donnelly, P. (2018). Identifying loci affecting trait
541 variability and detecting interactions in genome-wide association studies. *Nat. Genet.* *50*,
542 1608–1614.
- 543 19. Dumitrascu, B., Darnell, G., Ayroles, J., and Engelhardt, B.E. (2019). Statistical tests for
544 detecting variance effects in quantitative trait studies. *Bioinformatics* *35*, 200–210.
- 545 20. Corty, R.W., and Valdar, W. (2018). QTL mapping on a background of variance
546 heterogeneity. *G3 Genes, Genomes, Genet.* *8*, 3767–3782.
- 547 21. Levene, H. (1960). Robust testes for equality of variances. *Contrib. to Probab. Stat.* 278–
548 292.
- 549 22. Brown, M.B., and Forsythe, A.B. (1974). Robust tests for the equality of variances. *J. Am.*
550 *Stat. Assoc.* *69*, 364–367.
- 551 23. Soave, D., and Sun, L. (2017). A generalized Levene’s scale test for variance
552 heterogeneity in the presence of sample correlation and group uncertainty. *Biometrics* *73*,
553 960–971.
- 554 24. Glejser, H. (1969). A New Test for Heteroskedasticity. *J. Am. Stat. Assoc.* *64*, 316.
- 555 25. Pietrosanu, M., Gao, J., Kong, L., Jiang, B., and Niu, D. (2020). Advanced algorithms for
556 penalized quantile and composite quantile regression. *Comput. Stat.* 2020 361 *36*, 333–346.
- 557 26. Zhang, F., Chen, W., Zhu, Z., Zhang, Q., Nabais, M.F., Qi, T., Deary, I.J., Wray, N.R.,
558 Visscher, P.M., McRae, A.F., et al. (2019). OSCA: a tool for omic-data-based complex trait
559 analysis. *Genome Biol.* 2019 201 *20*, 1–13.
- 560 27. Zhu, Z., Zhang, F., Hu, H., Bakshi, A., Robinson, M.R., Powell, J.E., Montgomery, G.W.,
561 Goddard, M.E., Wray, N.R., Visscher, P.M., et al. (2016). Integration of summary data from
562 GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* *48*, 481–487.
- 563 28. Oehlert, G.W. (1992). A Note on the Delta Method. *Source Am. Stat.* *46*, 27–29.

- 564 29. White, H. (1980). A Heteroskedasticity-Consistent Covariance Matrix Estimator and a
565 Direct Test for Heteroskedasticity. *Econometrica* 48, 817.
- 566 30. Hunter, D.R., and Lange, K. (2000). Quantile Regression via an MM Algorithm. *J. Comput.*
567 *Graph. Stat.* 9, 60.
- 568 31. Guennebaud, G., Jacob, B., and others (2010). Eigen v3.
- 569 32. Band, G., and Marchini, J. (2018). BGEN: a binary file format for imputed genotype and
570 haplotype data. *BioRxiv* 308296.
- 571 33. Morris, T.P., White, I.R., and Crowther, M.J. (2019). Using simulation studies to evaluate
572 statistical methods. *Stat. Med.* 38, 2074–2102.
- 573 34. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
574 Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018). The UK Biobank resource with deep
575 phenotyping and genomic data. *Nature* 562, 203–209.
- 576 35. Howie, B., Marchini, J., and Stephens, M. (2011). Genotype imputation with thousands
577 of genomes. *G3 Genes, Genomes, Genet.* 1, 457–470.
- 578 36. Mitchell, R.E., Hemani, G., Dudding, T., Corbin, L., Harrison, S., and Paternoster, L. UK
579 Biobank Genetic Data: MRC-IEU Quality Control, version 2, 18/01/2019.
- 580 37. Fry, D., Almond, R., Moffat, S., Gordon, M., and Singh, P. (2019). UK Biobank Biomarker
581 Project Companion Document to Accompany Serum Biomarker Data.
- 582 38. Cassidy, S., Chau, J.Y., Catt, M., Bauman, A., and Trenell, M.I. (2016). Cross-sectional
583 study of diet, physical activity, television viewing and sleep duration in 233 110 adults from
584 the UK Biobank; the behavioural phenotype of cardiovascular disease and type 2 diabetes.
585 *BMJ Open* 6, e010038.
- 586 39. Elsworth, B., Lyon, M., Alexander, T., Liu, Y., Matthews, P., Hallett, J., Bates, P., Palmer,
587 T., Haberland, V., Davey Smith, G., et al. (2020). The MRC IEU OpenGWAS data

- 588 infrastructure. *BioRxiv* 2020.08.10.244293.
- 589 40. Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Bentley, D.R., Chakravarti, A.,
590 Clark, A.G., Donnelly, P., Eichler, E.E., Flicek, P., et al. (2015). A global reference for human
591 genetic variation. *Nat.* 2015 5267571 526, 68–74.
- 592 41. Hemani, G., Powell, J.E., Wang, H., Shakhbazov, K., Westra, H.-J., Esko, T., Henders, A.K.,
593 McRae, A.F., Martin, N.G., Metspalu, A., et al. (2021). Phantom epistasis between unlinked
594 loci. *Nat.* 2021 5967871 596, E1–E3.
- 595 42. Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach to
596 variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser.*
597 *B (Statistical Methodology)*. 82, 1273–1300.
- 598 43. Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing
599 genomic features. *Bioinforma. Appl. NOTE* 26, 841–842.
- 600 44. Tweedie, S., Braschi, B., Gray, K., Jones, T.E.M., Seal, R.L., Yates, B., and Bruford, E.A.
601 (2021). Genenames.org: The HGNC and VGNC resources in 2021. *Nucleic Acids Res.* 49,
602 D939–D946.
- 603 45. Vösa, U., Claringbould, A., Westra, H.-J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,
604 Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL analyses
605 identify thousands of genetic loci and polygenic scores that regulate blood gene expression.
606 *Nat. Genet.* 2021 539 53, 1300–1310.
- 607 46. GTEx Portal, <https://gtexportal.org>.
- 608 47. Campos, G. de los, Sorensen, D.A., and Toro, M.A. (2019). Imperfect Linkage
609 Disequilibrium Generates Phantom Epistasis (& Perils of Big Data). *G3 Genes, Genomes,*
610 *Genet.* 9, 1429–1436.
- 611 48. Stender, S., Kozlitina, J., Nordestgaard, B.G., Tybjaerg-Hansen, A., Hobbs, H.H., and

612 Cohen, J.C. (2017). Adiposity Amplifies the Genetic Risk of Fatty Liver Disease Conferred by
613 Multiple Loci HHS Public Access Author manuscript. *Nat Genet* 49, 842–847.

614 49. Viitasalo, A., Pihlajamaki, J., Lindi, V., Atalay, M., Kaminska, D., Joro, R., and Lakka, T.A.
615 (2015). Associations of I148M variant in PNPLA3 gene with plasma ALT levels during 2-year
616 follow-up in normal weight and overweight children: The PANIC Study. *Pediatr. Obes.* 10,
617 84–90.

618 50. Döring, A., Gieger, C., Mehta, D., Gohlke, H., Prokisch, H., Coassin, S., Fischer, G., Henke,
619 K., Klopp, N., Kronenberg, F., et al. (2008). SLC2A9 influences uric acid concentrations with
620 pronounced sex-specific effects. *Nat. Genet.* 2008 404 40, 430–436.

621 51. Ferrières, J., Sing, C.F., Roy, M., Davignon, J., and Lussier-Cacan, S. (1994).
622 Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-
623 specific effects. *Arterioscler. Thromb. a J. Vasc. Biol.* 14, 1553–1560.

624 52. Ruth, K.S., Day, F.R., Tyrrell, J., Thompson, D.J., Wood, A.R., Mahajan, A., Beaumont,
625 R.N., Wittemans, L., Martin, S., Busch, A.S., et al. (2020). Using human genetics to
626 understand the disease impacts of testosterone in men and women. *Nat. Med.* 2020 262 26,
627 252–258.

628 53. Masuda, M., Okuda, K., Ikeda, D.D., Hishigaki, H., and Fujiwara, T. (2015). Interaction of
629 genetic markers associated with serum alkaline phosphatase levels in the Japanese
630 population. *Hum. Genome Var.* 2015 21 2, 1–6.

631 54. Langman, M.J.S., Leuthold, E., Robson, E.B., Harris, J., Luffman, J.E., and Harris, H. (1966).
632 Influence of diet on the “intestinal” component of serum alkaline phosphates in people of
633 different ABO blood groups and secretor status. *Nature* 212, 41–43.

634 55. Abul-Husn, N.S., Cheng, X., Li, A.H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J.,
635 Stender, S., Wood, G.C., et al. (2018). A Protein-Truncating HSD17B13 Variant and

- 636 Protection from Chronic Liver Disease. *NEJM* 378, 1096–1106.
- 637 56. Gellert-Kristensen, H., Richardson, T.G., Davey Smith, G., Nordestgaard, B.G., Tybjærg-
638 Hansen, A., and Stender, S. (2020). Combined Effect of PNPLA3, TM6SF2, and HSD17B13
639 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
640 *Hepatology* 72, 845–856.
- 641 57. Bayer, P.M., Hotschek, H., and Knoth, E. (1980). Intestinal alkaline phosphatase and the
642 ABO blood group system--a new aspect. *Clin. Chim. Acta.* 108, 81–87.
- 643 58. Nakano, T., Shimanuki, T., Matsushita, M., Koyama, I., Inoue, I., Katayama, S., Alpers,
644 D.H., and Komoda, T. (2006). Involvement of intestinal alkaline phosphatase in serum
645 apolipoprotein B-48 level and its association with ABO and secretor blood group types.
646 *Biochem. Biophys. Res. Commun.* 341, 33–38.
- 647 59. Neale, B., et al. UK Biobank GWAS, <http://www.nealelab.is/uk-biobank>
- 648 60. Kanai, M., Akiyama, M., Takahashi, A., Matoba, N., Momozawa, Y., Ikeda, M., Iwata, N.,
649 Ikegawa, S., Hirata, M., Matsuda, K., et al. (2018). Genetic analysis of quantitative traits in
650 the Japanese population links cell types to complex human diseases. *Nat. Genet.* 50, 390–
651 400.
- 652 61. Young, K.A., Palmer, N.D., Fingerlin, T.E., Langefeld, C.D., Norris, J.M., Wang, N., Xiang,
653 A.H., Guo, X., Williams, A.H., Chen, Y.D.I., et al. (2019). Genome-Wide Association Study
654 Identifies Loci for Liver Enzyme Concentrations in Mexican-Americans: The GUARDIAN
655 Consortium. *Obesity (Silver Spring)*. 27, 1331.
- 656 62. Chambers, J.C., Zhang, W., Sehmi, J.S., Li, X., Wass, M.N., Van der Harst, P., Holm, H.,
657 Sanna, S., Kavousi, M., Baumeister, S.E., et al. (2011). Genome-wide association study
658 identifies loci influencing concentrations of liver enzymes in plasma. *Nat. Genet.* 2011 4311
659 43, 1131–1138.

- 660 63. Xu, Z.M., and Burgess, S. (2020). Polygenic modelling of treatment effect heterogeneity.
661 *Genet. Epidemiol.* *44*, 868–879.
- 662 64. Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P.C., Hurle, M.R., Gutteridge, A.,
663 Erola, P., Liu, Y., Luo, S., et al. (2020). Phenome-wide Mendelian randomization mapping the
664 influence of the plasma proteome on complex diseases. *Nat. Genet.* 2020 5210 52, 1122–
665 1131.
- 666 65. Cao, Y., Wei, P., Bailey, M., Kauwe, J.S.K., and Maxwell, T.J. (2014). A versatile omnibus
667 test for detecting mean and variance heterogeneity. *Genet. Epidemiol.* *38*, 51–59.
- 668 66. Ek, W.E., Rask-Andersen, M., Karlsson, T., Enroth, S., Gyllensten, U., and Johansson, Å.
669 (2018). Genetic variants influencing phenotypic variance heterogeneity. *Hum. Mol. Genet.*
670 *27*, 799–810.
- 671 67. Rees, J.M.B., Foley, C.N., and Burgess, S. (2020). Factorial Mendelian randomization:
672 using genetic variants to assess interactions. *Int. J. Epidemiol.* *49*, 1147–1158.
- 673 68. Lyon, M.S., Andrews, S.J., Elsworth, B., Gaunt, T.R., Hemani, G., and Marcora, E. (2021).
674 The variant call format provides efficient and robust storage of GWAS summary statistics.
675 *Genome Biol.* *22*, 32.
676

677 **Figure 1. Variance effect estimate accuracy and confidence interval coverage**

678 Variance effect estimate accuracy (A, B) and 95% confidence interval coverage (C, D) of
679 simulated genotypes with linear effect on outcome variance (A, C) or interaction effect (B,
680 D). LAD-BF, least-absolute deviation regression Brown-Forsythe. OSCA-BF, original Brown-
681 Forsythe test implemented in OSCA²⁶ including effect estimate derived from the test P-
682 value²⁷. CI, confidence interval.

683 **Figure 2. Effect of top gene-environment interaction loci on trait mean and variance**

684 Per-allele effect of SNP stratified by modifier on outcome mean estimated with
685 heteroscedastic-consistent standard errors²⁹ and unstratified effect of SNP on variance
686 estimated using LAD-BF (genotype 0 vs 1 and 0 vs 2) with or without adjustment for the
687 interaction term. All estimates were adjusted for age, sex (except for rs1065853, rs1799941
688 and rs938555 on variance as the modifier was sex) and top ten genetic principal
689 components. SD, standard deviation. CI, confidence interval. ALT, alanine aminotransferase.
690 LDL, low-density lipoprotein. BMI, body mass index. Low BMI, $\leq 26.7 \text{ kg/m}^2$. High BMI, $>$
691 26.7 kg/m^2 .





692 **Figure 3. Effect of top gene-gene interaction loci on trait mean and variance**

693 Per allele effect of SNP stratified by modifier on outcome mean estimated with
694 heteroscedastic-consistent standard errors²⁹ and unstratified effect of SNP on variance
695 estimated using LAD-BF (genotype 0 vs 1 and 0 vs 2) with or without adjustment for the
696 interaction term. All estimates were adjusted for age, sex, and top ten genetic principal
697 components. SD, standard deviation. CI, confidence interval. ALP, alkaline phosphatase. ALT,
698 alanine aminotransferase. AST, aspartate aminotransferase. GGT, gamma
699 glutamyltransferase.

700 **Table 1. Simulation studies of the Brown-Forsythe test**


Figure	Aim	Conditions
1	Determine variance effect estimate accuracy and confidence interval coverage	Increasing interaction effect size.
S2	Estimate power of variance tests to detect interaction effects using normal/non-normal outcomes	Increasing interaction effect size. Normal, log-normal, and t-distribution residuals
S3	Estimate type I error of variance tests with normal/non-normal outcomes	Increasing SNP minor allele frequency. Normal, log-normal, t-distribution, and mixed-normal residuals
S4	Adjusting for interaction effect on variance effect estimate	With/without adjustment for modifier and interaction term in first-stage model
S5	Estimate model runtime performance	Increasing number of CPU threads

701 SNP, single-nucleotide polymorphism. Log, natural logarithm. CPU, central processing unit.




ALT
PNPLA3 (rs738409)
BMI

Mean




ALT
PNPLA3 (rs738409)
BMI

Variance




ALT
TM6SF2 (rs58542926)
BMI

Mean




ALT
TM6SF2 (rs58542926)
BMI

Variance




LDL
APOE (rs1065853)
Sex

Mean



LDL
APOE (rs1065853)
Sex

Variance




Interaction

- Unadjusted
- ▲ Adjusted


Testosterone
SHBG (rs1799941)
Sex

Mean




Testosterone
SHBG (rs1799941)
Sex

Variance



Urate
SLC2A9 (rs938555)
Sex

Mean



Urate
SLC2A9 (rs938555)
Sex

Variance

